Patient Support Services Contact Us
Products_and_Pipeline_Banner

At Coherus, we put patients first.

We are dedicated to improving the availability of high-value, high-quality therapeutics. Our pipeline spans multiple therapeutic areas including oncology, immunology, and ophthalmology.

Our first product, UDENYCA® (pegfilgrastim-cbqv), is an FDA-approved pegfilgrastim biosimilar.

With our expansion into immuno-oncology, toripalimab clinical trial results are expected over the next several years from a broad registrational clinical development program across multiple tumor types including cancers of the lung, esophagus, bladder, nasopharynx, stomach, breast, liver, and skin.

Our strategy is to invest cash flows from our commercial biosimilar business to build a fast-follower immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.

Product/
Candidate
DescriptionPhase 1/2Phase 3BLA SubmissionApproved/
Marketed*
ONCOLOGY PIPELINE
Product/
Candidate
DescriptionPhase 1/2Phase 3BLA SubmissionApproved/Marketed
UDENYCA®pegfilgrastim
biosimilar
Toripalimab
Licensed from
Junshi
anti-PD-1
antibody
Licensed from
Innovent
bevacizumab
biosimilar
Immunology Pipeline
Product/
Candidate
DescriptionPhase 1/2Phase 3BLA SubmissionApproved/Marketed
CHS-1420adalimumab
biosimilar
Ophthalmology Pipeline
Product/
Candidate
DescriptionPhase 1/2Phase 3BLA SubmissionApproved/Marketed
Licensed
from Bioeq
ranibizumab
biosimilar
* United States